VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Erenumab in migraine with or without aura: cardiovascular safety

Stewart Tepper • 24 May 2020
EAN 2020
Headache Antibodies Erenumab
Treatment Trial Updates

Stewart Tepper, MD, Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, discusses the cardiovascular and cerebrovascular adverse events of erenumab in patients with migraine with or without a history of aura. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Stewart Tepper

5:55
Increased placebo response over time in migraine preventive trials
Stewart Tepper • 17 Jun 2022
11:31
Therapeutic landscape for cluster headache
Stewart Tepper • 24 May 2020
20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper • 24 May 2020
9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020

Related Videos

5:45
New European Academy of Neurology guidelines for cluster headache treatment
Rigmor Hojland Jensen • 19 Oct 2023
1:36
New cluster headache treatments are needed to better meet the needs of patients
Rigmor Hojland Jensen • 19 Oct 2023
2:25
Challenges facing trigeminal autonomic cephalalgia diagnosis
Elizabeth Leroux • 18 Oct 2023
3:17
Diagnostic criteria for trigeminal autonomic cephalalgias
Elizabeth Leroux • 18 Oct 2023
The content of VJNeurology is intended for healthcare professionals